Bright Mnds: Positive Data from 1st-in-Human Phase 1 Study of Lead Compound

 BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders

-- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study

-- Proof of Mechanism and target engagement in the brain was established using blood biomarkers and qEEG

-- In qEEG, BMB-101 demonstrated robust increase in central delta power and robust reduction in central alpha and beta power in active group, as previously reported for Anti-Epileptic Drugs (AEDs) in healthy individuals

-- Company to host webcast to discuss findings of the Phase 1 study today, August 8, 2023, at 4:30pm ET

Bright Minds management will host a webcast to discuss the Phase 1 study as follows:

Date:		Tuesday, August 8, 2023
Time:		4:30pm ET
Webcast link:		Click here https://finance.yahoo.com/news/bright-minds-biosciences-announces-positive-105000040.html